Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Chromadex Corp CS (NQ: CDXC )

2.955 +0.175 (+6.29%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Chromadex Corp CS

< Previous 1 2 3 4 Next >
ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel
From ChromaDex Corporation
Via Business Wire
ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August
From ChromaDex Corporation
Via Business Wire
ChromaDex to Join Russell 2000® Index
From ChromaDex Corporation
Via Business Wire
Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)
From ChromaDex Corporation
Via Business Wire
ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)
From ChromaDex Corporation
Via Business Wire
ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)
From ChromaDex Corporation
Via Business Wire
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024
From ChromaDex Corporation
Via Business Wire
ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
From ChromaDex Corporation
Via Business Wire
ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award
From ChromaDex Corporation
Via Business Wire
ChromaDex Corporation Reports First Quarter 2024 Financial Results
From ChromaDex Corporation
Via Business Wire
ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®
From ChromaDex Corporation
Via Business Wire
ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement
From ChromaDex Corporation
Via Business Wire
ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
From ChromaDex Corporation
Via Business Wire
ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market
From ChromaDex Corporation
Via Business Wire
ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program
From ChromaDex Corporation
Via Business Wire
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
From ChromaDex Corporation
Via Business Wire
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
From ChromaDex Corporation
Via Business Wire
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024
From ChromaDex Corporation
Via Business Wire
ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
From ChromaDex Corporation
Via Business Wire
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®
From ChromaDex Corporation
Via Business Wire
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)
From ChromaDex Corporation
Via Business Wire
Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients
From ChromaDex Corporation
Via Business Wire
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023
From ChromaDex Corporation
Via Business Wire
ChromaDex Corporation Reports Third Quarter 2023 Financial Results
From ChromaDex Corporation
Via Business Wire
ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide
From ChromaDex Corporation
Via Business Wire
ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
From ChromaDex Corporation
Via Business Wire
ChromaDex and Zesty Paws® Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ Line
From ChromaDex Corporation
Via Business Wire
Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMN
From ChromaDex Corporation
Via Business Wire
A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients
From ChromaDex Corporation
Via Business Wire
ChromaDex Corporation Reports Second Quarter 2023 Financial Results
From ChromaDex Corporation
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.